Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,062 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination 400 Clear all

Conditions: Advanced Nonhematologic Malignancies
Interventions: MLN2480, MLN0128, Alisertib, Paclitaxel, Cetuximab, Irinotecan; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Breast Cancer
Interventions: Exemestane, Celecoxib, Correlative studies; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Asthma
Interventions: budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone; Drug
Lead sponsor: Gelb, Arthur F., M.D.; Individual
Eligibility: 10 Years to 95 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Lakewood, California

Conditions: Postoperative Pain, Abdominoplasty Surgery, Multimodal Analgesia
Interventions: MMA regimen, ZYNRELEF kit components for administration, HTX-011, Bupivacaine Hydrochloride; Drug · Device
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Bellaire, Texas • San Antonio, Texas

Conditions: Carcinoma
Interventions: Sorafenib 100 mg (50-mg tablet), Sorafenib 200 mg (50-mg tablet), Sorafenib 400 mg (50-mg tablet), Sorafenib 400 mg (200-mg tablet), Sorafenib 400 mg (Expansion); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Nashville, Tennessee • Madison, Wisconsin

Conditions: Intraabdominal Infections
Interventions: Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate, Moxifloxacin placebo, Ertapenem placebo, Amoxicillin/Clavulanate placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: San Diego, California • Springfield, Massachusetts

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Cetuximab; Drug
Lead sponsor: Veeda Oncology; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Timeline: Ends 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Neoplasms
Interventions: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat, Exemestane, Fulvestrant, Ipatasertib, Tamoxifen, Abemaciclib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more

Conditions: Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
Interventions: ABT-450, ABT-333, ABT-267, Ribavirin, Ritonavir; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 60
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 52 more

Conditions: Carcinoma, Hepatocellular
Interventions: LY2157299, Sorafenib, Ramucirumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 10
States / cities: Fayetteville, Arkansas • San Francisco, California • Washington D.C., District of Columbia + 6 more

Conditions: Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: PU-H71, Ruxolitinib; Drug
Lead sponsor: Samus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: New Haven, Connecticut • New Orleans, Louisiana • Ann Arbor, Michigan + 7 more

Conditions: Transcutaneous Spinal Stimulation, Walking, Spasticity, Human, Spinal Cord Injuries
Interventions: Transcutaneous spinal stimulation; Device
Lead sponsor: Shepherd Center, Atlanta GA; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypercholesterolemia
Interventions: CAT-2054, Placebo, Atorvastatin; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 34
States / cities: Muscle Shoals, Alabama • Huntington Park, California • Lomita, California + 28 more

Conditions: Hepatitis C, HIV-1-infection, Liver Diseases
Interventions: Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy; Drug · Other
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: Hepatitis C, Chronic
Interventions: Sofosbuvir, RBV, PEG; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 44
States / cities: Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more

Conditions: Pancreatic Cancer
Interventions: Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg, Phase II: XB2001 1000 mg, Phase II: Placebo; Biological
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 30
States / cities: Tucson, Arizona • Burbank, California • Cerritos, California + 26 more

Conditions: Pancreatic Cancer
Interventions: ANO31905, AG [gemcitabine+nab-paclitaxel], mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]; Drug
Lead sponsor: Anova Innovation Limited; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • Plantation, Florida • San Antonio, Texas

Conditions: Advanced Gastrointestinal Stromal Tumor (GIST)
Interventions: BGJ398, Imatinib Mesylate; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 7
States / cities: Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 4 more

Conditions: Pancreatic Cancer
Interventions: Pegilodecakin, FOLFOX; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 57
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 49 more

Conditions: Human Immunodeficiency Virus
Interventions: emtricitabine/tenofovir disoproxil fumarate; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Postmenopausal Osteoporosis
Interventions: Strength/Weight Training & Drug/Supplement, Drug/Supplement only; Other · Combination Product
Lead sponsor: University of Nebraska; Other
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 4
States / cities: Kearney, Nebraska • Lincoln, Nebraska • Omaha, Nebraska + 1 more

Conditions: Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions: Entospletinib, Placebo, Cytarabine, Anthracycline; Drug
Lead sponsor: Kronos Bio; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Indianapolis, Indiana + 7 more

Conditions: Leukemia, Myeloid, Chronic
Interventions: Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer
Interventions: Brivanib + Cetuximab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 5
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 2 more

Search by objective public record fields.

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Cohort 2 (Abdominoplasty) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011)

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Spinal Cord Stimulation to Augment Activity Based Therapy

A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Post-Exposure Prophylaxis in Health Care Workers

Prevention of Osteoporosis in Breast Cancer Survivors

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies